SAN MATEO, Calif. — Vivace Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class cancer therapies that target the Hippo signaling pathway, today announced a series of leadership appointments that position the company for its next phase of growth as it prepares to advance its lead candidate, VT3989, into the pivotal Phase...

Bergen, Norway, 24 August 2026 – Pluvia Biotech (Pluvia), a biotechnology company developing novel therapies for phenylketonuria (PKU), today announced the appointment of Deborah Ramsdell as Chief Executive Officer (CEO). Current CEO Willem van Weperen will transition to Pluvia’s Board of Directors, where he will remain involved as the company prepares...

AUSTIN, Texas — Frances Arnold, PhD, winner of the 2018 Nobel Prize in Chemistry, has been awarded a two-year grant by the Foundation for Angelman Syndrome Therapeutics (FAST) to develop new molecular tools that could help advance future RNA-targeted therapeutics for Angelman syndrome. The project will apply directed evolution, the...